Prenetics Global Limited (NASDAQ:PRE) shares traded -16.74% lower at $1.89 on Wall Street last session.
In accordance with the data, 2 analysts cover Prenetics Global Limited (NASDAQ:PRE). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $8.10, we find $11.55. Given the previous closing price of $2.27, this indicates a potential upside of 408.81 percent. PRE stock price is now -16.61% away from the 50-day moving average and -56.11% away from the 200-day moving average. The market capitalization of the company currently stands at $209.79M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
It has been rated a hold by 0 analysts and a buy by 2. Brokers who have rated the stock have averaged $11.55 as their price target over the next twelve months.
.
A total of 31.38% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PRE stock. A new stake in Prenetics Global Limited shares was purchased by VIDENT INVESTMENT ADVISORY, LLC during the first quarter worth $31,000. In total, there are 18 active investors with 9.30% ownership of the company’s stock.
Prenetics Global Limited (NASDAQ: PRE) opened at $2.1100 on Wednesday. During the past 12 months, Prenetics Global Limited has had a low of $1.24 and a high of $8.75. As of last week, the company has a debt-to-equity ratio of 0.07, a current ratio of 5.00, and a quick ratio of 4.90. The fifty day moving average price for PRE is $2.2666 and a two-hundred day moving average price translates $4.3059 for the stock.
The latest earnings results from Prenetics Global Limited (NASDAQ: PRE) was released for Jun, 2022. According to the Diagnostics & Research Company, earnings per share came in at $0.04, beating analysts’ expectations of -$0.62 by 0.66. This compares to -$2.65 EPS in the same period last year. The net profit margin was -96.40% and return on equity was 278.30% for PRE. The company reported revenue of $79.68 million for the quarter, compared to $74.66 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 6.73 percent. For the current quarter, analysts expect PRE to generate $66.58M in revenue.
Prenetics Global Limited(PRE) Company Profile
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company’s products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
